Tangoe (TNGO) Takes Another Blow
Tweet
Share
E-mail
Get Alerts TNGO Hot Sheet
Price: $5.10 --0%
Rating Summary:
5 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 8
Rating Summary:
5 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 8
Join SI Premium – FREE
Shares of Tangoe, Inc. (NASDAQ: TNGO) are taking another leg lower after another independent research firm trashed the company.
In a new report, Copperfield Research said "After doing a deep dive into Tangoe's financials, it is our belief that the company has significantly misrepresented its de novo growth rate, while demonstrating many of the telltale shenanigans and behavior that tends to be a harbinger for blow ups. We believe that an SEC investigation may be warranted based on our belief Tangoe publicly misrepresented its organic growth rates, and altered material biographic information, in front of a large secondary offering."
Tangoe was the recent target of theStreetSweeper.org, which published the first article in a two-part series last week.
Link to Copperfield Research report.
Shares of TNGO are down 11 percent.
In a new report, Copperfield Research said "After doing a deep dive into Tangoe's financials, it is our belief that the company has significantly misrepresented its de novo growth rate, while demonstrating many of the telltale shenanigans and behavior that tends to be a harbinger for blow ups. We believe that an SEC investigation may be warranted based on our belief Tangoe publicly misrepresented its organic growth rates, and altered material biographic information, in front of a large secondary offering."
Tangoe was the recent target of theStreetSweeper.org, which published the first article in a two-part series last week.
Link to Copperfield Research report.
Shares of TNGO are down 11 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- First Bancorp to acquire First Carolina Bancshares for $166M
- SS Innovations names Sarah M. Romano as CFO, effective August 3
- Hemab shares sutacimig Phase 2 data at ISTH 2026 congress
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
TheStreetSweeperSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
